Illumina (ILMN)
(Delayed Data from NSDQ)
$117.61 USD
+3.12 (2.73%)
Updated Jul 22, 2024 04:00 PM ET
After-Market: $117.69 +0.08 (0.07%) 7:58 PM ET
2-Buy of 5 2
D Value C Growth D Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$117.61 USD
+3.12 (2.73%)
Updated Jul 22, 2024 04:00 PM ET
After-Market: $117.69 +0.08 (0.07%) 7:58 PM ET
2-Buy of 5 2
D Value C Growth D Momentum C VGM
Zacks News
Why Illumina (ILMN) Could Beat Earnings Estimates Again
by Zacks Equity Research
Illumina (ILMN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Wall Street Analysts Think Illumina (ILMN) Could Surge 27.02%: Read This Before Placing a Bet
by Zacks Equity Research
The consensus price target hints at a 27% upside potential for Illumina (ILMN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
by Zacks Equity Research
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Illumina (ILMN) Upgraded to Buy: Here's Why
by Zacks Equity Research
Illumina (ILMN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Illumina (ILMN) Buys Fluent, Grows in Single Cell Research
by Zacks Equity Research
By integrating Fluent's unique technology with Illumina's (ILMN) sequencing and informatics solutions, researchers are likely to gain access to a comprehensive solution for single-cell multiomic analysis.
Illumina (ILMN) Rises on Conclusion of GRAIL Divestment
by Zacks Equity Research
With the divestment now over, we expect Illumina (ILMN) to soar again on the assumption that the company will start to focus on its legacy businesses.
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Illumina (ILMN) Advances in NGS With DRAGEN v4.3 Launch
by Zacks Equity Research
One of the standout features of Illumina's (ILMN) DRAGEN v4.3 is its machine-learning mosaic model.
The Zacks Analyst Blog Highlights Union Pacific, Freeport-McMoRan, Block, Xcel and Illumina
by Zacks Equity Research
Union Pacific, Freeport-McMoRan, Block, Xcel and Illumina are included in this Analyst Blog.
Top Research Reports for Union Pacific, Freeport-McMoRan & Block
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Union Pacific Corporation (UNP), Freeport-McMoRan Inc. (FCX) and Block, Inc. (SQ).
Illumina (ILMN) Q1 Earnings Beat, Adjusted Operating Loss Widens
by Zacks Equity Research
Illumina (ILMN) surpasses expectations in the first quarter in a challenging global macroeconomic environment.
Illumina (ILMN) Reports Q1 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
Although the revenue and EPS for Illumina (ILMN) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Will These 5 MedTech Stocks Beat Forecasts This Earnings Season?
by Urmimala Biswas
Here is a sneak peek into how the five MedTech stocks, HOLX, ZBH, ILMN, TFX and BRKR, are expected to fare in their quarterly results slated to be released tomorrow.
Analysts Estimate AbCellera Biologics Inc. (ABCL) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
AbCellera Biologics (ABCL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Gear Up for Illumina (ILMN) Q1 Earnings: Wall Street Estimates for Key Metrics
by Zacks Equity Research
Evaluate the expected performance of Illumina (ILMN) for the quarter ended March 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Illumina (ILMN) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Illumina (ILMN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises
by Zacks Equity Research
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Can Illumina (ILMN) Keep the Earnings Surprise Streak Alive?
by Zacks Equity Research
Illumina (ILMN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises
by Zacks Equity Research
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
by Zacks Equity Research
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Exact Sciences (EXAS) Up 4.2% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Exact Sciences (EXAS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Is Invesco S&P 500 Equal Weight Health Care ETF (RSPH) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for RSPH
Should You Invest in the Invesco Biotechnology & Genome ETF (PBE)?
by Zacks Equity Research
Sector ETF report for PBE
Should You Invest in the Invesco S&P 500 Equal Weight Health Care ETF (RSPH)?
by Zacks Equity Research
Sector ETF report for RSPH
Is Invesco Biotechnology & Genome ETF (PBE) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for PBE